XML 79 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9
Business Combinations (Pro Forma Information) (Details) (NPS Pharma, USD $)
In Millions, except Per Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
NPS Pharma
   
Pro Forma Information    
Revenues $ 1,518.3us-gaap_BusinessAcquisitionsProFormaRevenue
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
$ 1,390.8us-gaap_BusinessAcquisitionsProFormaRevenue
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Net income from continuing operations 358.8us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
85.8us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Net income from continuing operations per share - basic $ 0.609us-gaap_BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasic
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
$ 0.147us-gaap_BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasic
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Net income from continuing operations per share - diluted $ 0.605us-gaap_BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareDiluted
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
$ 0.146us-gaap_BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareDiluted
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Pro Forma Data Adjustments    
An adjustment to increase amortization of intangible assets (21.1)shpgf_BusinessAcquisitionProFormaDataAdjustmentsAmortizationOfIntangibleAsset
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
(42.3)shpgf_BusinessAcquisitionProFormaDataAdjustmentsAmortizationOfIntangibleAsset
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Increase/(decrease) to net income to reflect acquisition related costs 106.8shpgf_BusinessAcquisitionProFormaDataAdjustmentsAcquisitionAndIntegrationCosts
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
(106.8)shpgf_BusinessAcquisitionProFormaDataAdjustmentsAcquisitionAndIntegrationCosts
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Decrease to net income to reflect the additional interest expense   (5.6)shpgf_BusinessAcquisitionProFormaDataAdjustmentsInterestIncomeExpense
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory. $ 6.1shpgf_Businessacquisitionproformadataadjustmentsinventoryfairvalue
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
$ (6.1)shpgf_Businessacquisitionproformadataadjustmentsinventoryfairvalue
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember